Observational studyPathogens (Basel, Switzerland)2026
Clinical Characteristics of Carbapenem-Resistant Gram-Negative Bloodstream Infections and Fungemia Among High-Risk Pediatric Patients Receiving Empirical Antifungal Therapy.
Observational study in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealthcare-associated bloodstream infections remain a significant cause of morbidity and mortality in hospitalized children, particularly in intensive care settings. Carbapenem-resistant Gram-negative bacterial (CR-GNB) bloodstream infections and fungemia may present with overlapping clinical features. This can complicate empirical treatment decisions in resource-limited settings. This study evaluated baseline clinical and laboratory characteristics associated with CR-GNB bloodstream infections and fungemia among high-risk pediatric patients.
methodsThis retrospective observational cohort study included pediatric patients aged 0-18 years who were evaluated at the time of clinical deterioration and blood culture collection for suspected healthcare-associated bloodstream infection before empirical antifungal therapy initiation for the index episode. Patients who subsequently received empirical antifungal therapy between May 2023 and September 2025 were retrospectively screened. Of the 240 screened patients, 103 met the inclusion criteria and were classified into CR-GNB (n = 56) and fungemia (n = 47) groups based on blood culture results. Clinical, laboratory, and microbiological data were analyzed using univariate and multivariable statistical methods.
resultsObserved 90-day all-cause mortality was higher in the CR-GNB group than in the fungemia group (50.0% vs. 29.8%,
conclusionIn this selected high-risk cohort, thrombocytopenia and central venous catheter use were associated with CR-GNB bloodstream infections. Observed mortality was higher in the CR-GNB group, but this finding should be interpreted with caution as adjusted mortality analysis and standardized severity assessment were not performed. These findings are hypothesis-generating and require validation in larger prospective studies before guiding empirical treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.